Sunphenon in Progressive Forms of Multiple Sclerosis (SUPREMES)
Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis
Sponsor: Friedemann Paul
This PHASE2/PHASE3 trial investigates Multiple Sclerosis and is currently completed. Friedemann Paul leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2_PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Dec 2018 — May 2020 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Friedemann Paul
- TAIYO EUROPE
For direct contact, visit the study record on ClinicalTrials.gov .